Top

Journal of Ocular Biology, Diseases, and Informatics

Published in:

Open Access 01-06-2009 | Technical Perspectives

Neural protection by naturopathic compounds—an example of tetramethylpyrazine from retina to brain

Author: Zhiqun Tan

Published in: Journal of Ocular Biology, Diseases, and Informatics | Issue 2/2009

Abstract

Given the advantages of being stable in the ambient environment, being permeable to the blood–brain and/or blood–eye barriers and being convenient for administration, naturopathic compounds have growingly become promising therapeutic candidates for neural protection. Extracted from one of the most common Chinese herbal medicines, tetramethylpyrazine (TMP), also designated as ligustrazine, has been suggested to be neuroprotective in the central nervous system as well as the peripheral nerve network. Although the detailed molecular mechanisms of its efficacy for neural protection are understood limitedly, accumulating evidence suggests that antioxidative stress, antagonism for calcium, and suppression of pro-inflammatory factors contribute significantly to its neuroprotection. In animal studies, systemic administration of TMP (subcutaneous injection, 50 mg/kg) significantly blocked neuronal degeneration in hippocampus as well as the other vulnerable regions in brains of Sprague–Dawley rats following kainate-induced prolonged seizures. Results from us and others also demonstrated potent neuroprotective efficacy of TMP for retinal cells and robust benefits for brain in Alzheimer’s disease or other brain injury. These results suggest a promising prospect for TMP to be used as a treatment of specific neurodegenerative diseases. Given the assessment of the distribution, metabolism, excretion, and toxicity information that is already available on most neuroprotective naturopathic compounds such as TMP, it would not take much preclinical data to justify bringing such therapeutic compounds to clinical trials in humans.

Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature. 2006;443:796–802.PubMedCrossRef

Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006;8:1997–2006.PubMedCrossRef

Kazantsev AG. Cellular pathways leading to neuronal dysfunction and degeneration. Drug News Perspect. 2007;20:501–9.PubMedCrossRef

Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience. 2007;145:1233–48.PubMedCrossRef

Liu YH, Liu YF, Guo XX. Current studies on anti-endotoxic chemical components of traditional Chinese medicine in China. Acta Pharmacologica Sinica. 2001;22:1071–7.PubMed

Ho JW, Jie M. Pharmacological activity of cardiovascular agents from herbal medicine. Cardiovasc Hematol Agents Med Chem. 2007;5:273–7.PubMedCrossRef

Xu H, Shi DZ, Guan CY. Clinical application and pharmacological actions of ligustrazine. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;23:376–9.PubMed

Wang GJ. The change in the nailfold microcirculation in patients with acute cerebral thrombosis treated with ligustrazine. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1984;17:121–4.PubMed

Yan F, Luo R. Effects of ligustrazine on blood vessels and blood components. Zhong Yao Cai. 2002;25:143–5.PubMed

10.

Liu SF, Cai YN, Evans TW, McCormack DG, Barer GR, Barnes PJ. Ligustrazine is a vasodilator of human pulmonary and bronchial arteries. Eur J Pharmacol. 1990;191:345–50.PubMedCrossRef

11.

Pang PK, Shan JJ, Chiu KW. Tetramethylpyrazine, a calcium antagonist. Planta Med. 1996;62:431–5.PubMedCrossRef

12.

Zhang ZH, Yu SZ, Wang ZT, Zhao BL, Hou JW, Yang FJ, et al. Scavenging effects of tetramethylpyrazine on active oxygen free radicals. Zhongguo Yao Li Xue Bao. 1994;15:229–31.PubMed

13.

Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci. 2003;72:2465–72.PubMedCrossRef

14.

Ozaki Y. Antiinflammatory effect of tetramethylpyrazine and ferulic acid. Chem Pharm Bull (Tokyo). 1992;40:954–6.

15.

Chang Y, Hsiao G, Chen SH, Chen YC, Lin JH, Lin KH, et al. Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacologica Sinica. 2007;28:327–33.PubMedCrossRef

16.

Liao MH, Wu CC, Yen MH. Beneficial effects of tetramethylpyrazine, an active constituent of Chinese herbs, on rats with endotoxemia. Proc Natl Sci Counc Repub China B. 1998;22:46–54.PubMed

17.

Chiou GC, Yan HY, Lei XL, Li BH, Shen ZF. Ocular and cardiovascular pharmacology of tetramethylpyrazine isolated from Ligusticum wallichii Franch. Zhongguo Yao Li Xue Bao. 1991;12:99–104.PubMed

18.

Yang JN, Chen JM, Luo L, Lin SC, Li D, Hu SX. Tetramethylpyrazine protected photoreceptor cells of rats by modulating nuclear translocation of NF-kappaB. Acta Pharmacologica Sinica. 2005;26:887–92.PubMedCrossRef

19.

Yang Z, Zhang Q, Ge J, Tan Z. Protective effects of tetramethylpyrazine on rat retinal cell cultures. Neurochem Int. 2008;52:1176–87.PubMedCrossRef

20.

Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Iron-induced oxidative damage and apoptosis in cerebellar granule cells: attenuation by tetramethylpyrazine and ferulic acid. Eur J Pharmacol. 2003;467:41–7.PubMedCrossRef

21.

Shih YH, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS. Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. NeuroReport. 2002;13:515–9.PubMedCrossRef

22.

Liao SL, Kao TK, Chen WY, Lin YS, Chen SY, Raung SL, et al. Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci Lett. 2004;372:40–5.PubMedCrossRef

23.

Kao TK, Ou YC, Kuo JS, Chen WY, Liao SL, Wu CW, et al. Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats. Neurochem Int. 2006;48:166–76.PubMedCrossRef

24.

Fan LH, Wang KZ, Cheng B, Wang CS, Dang XQ. Anti-apoptotic and neuroprotective effects of Tetramethylpyrazine following spinal cord ischemia in rabbits. BMC Neurosci. 2006;7:48.PubMedCrossRef

25.

Zhang C, Wang SZ, Zuo PP, Cui X, Cai J. Protective effect of tetramethylpyrazine on learning and memory function in d-galactose-lesioned mice. Chin Med Sci J. 2004;19:180–4.PubMed

26.

Ni JW, Matsumoto K, Watanabe H. Tetramethylpyrazine improves spatial cognitive impairment induced by permanent occlusion of bilateral common carotid arteries or scopolamine in rats. Jpn J Pharmacol. 1995;67:137–41.PubMedCrossRef

27.

Sperk G. Kainic acid seizures in the rat. Prog Neurobiol. 1994;42:1–32.PubMedCrossRef

28.

Salinska E, Danysz W, Lazarewicz JW. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005;43:322–39.PubMed

29.

Casson RJ. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin Experiment Ophthalmol. 2006;34:54–63.PubMedCrossRef

30.

Tan Z, Tu W, Schreiber SS. Downregulation of free ubiquitin: a novel mechanism of p53 stabilization and neuronal cell death. Brain Res Mol Brain Res. 2001;91:179–88.PubMedCrossRef

31.

Tan Z, Levid J, Schreiber SS. Increased expression of Fas (CD95/APO-1) in adult rat brain after kainate-induced seizures. NeuroReport. 2001;12:1979–82.PubMedCrossRef

32.

Quach N, Chan T, Lu TA, Schreiber SS, Tan Z. Induction of DNA repair proteins, Ref-1 and XRCC1, in adult rat brain following kainic acid-induced seizures. Brain Res. 2005;1042:236–40.PubMedCrossRef

33.

Tan Z, Sankar R, Shin D, Sun N, Liu H, Wasterlain CG, et al. Differential induction of p53 in immature and adult rat brain following lithium-pilocarpine status epilepticus. Brain Res. 2002;928:187–93.PubMedCrossRef

34.

Dehmelt L, Halpain S. Actin and microtubules in neurite initiation: are MAPs the missing link? J Neurobiol. 2004;58:18–33.PubMedCrossRef

35.

Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001;98:6336–41.PubMedCrossRef

36.

Qi X, Ackermann C, Sun D, Sheng M, Hou H. Physicochemical characterization and percutaneous delivery of 2, 3, 5, 6-tetramethylpyrazine. Int J Pharm. 2003;253:177–83.PubMedCrossRef

37.

Ren P, Huang X, Jiang YP. Effect of sijunzi decoction on motilin and pharmacokinetic characteristics of tetramethylpyrazine in rat model of spleen deficiency syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997;17:45–7.PubMed

38.

Lou YQ, Zhang H, Cao X, Chen ML. The pharmacokinetics and disposition of tetramethylpyrazine phosphate in dogs and rats. Yao Xue Xue Bao. 1986;21:481–7.PubMed

39.

Tsai TH, Liang C. Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis. Int J Pharm. 2001;216:61–6.PubMedCrossRef

40.

Huang X, Ren P, Wen AD, Wang LL, Zhang L, Gao F. Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I). World J Gastroenterol. 2000;6:384–91.PubMed

41.

Qi X, Ackermann C, Sun D, Liu R, Sheng M, Hou H. The prediction of plasma and brain levels of 2, 3, 5, 6-tetramethylpyrazine following transdermal application. AAPS PharmSci. 2002;4:E46.PubMedCrossRef

42.

Occelli E, Mariani L, Fontanella L, Corsico N. Substances with central nervous system activity. Derivatives of octahydro-1,4-dihydroxypyrrolo(1,2-a)pyrazine-6-carboxylic acids. Farmaco [Sci]. 1984;39:718–38.

43.

Adams TB, Doull J, Feron VJ, Goodman JI, Marnett LJ, Munro IC, et al. The FEMA GRAS assessment of pyrazine derivatives used as flavor ingredients. Flavor and Extract Manufacturers Association. Food Chem Toxicol. 2002;40:429–51.PubMedCrossRef

44.

Huang KJ, Williams WM. The pharmacology of Chinese herbs. Boca Raton: CRC; 1993.

45.

Tang X. Effect of ligustrazine on proliferative glomerulonephritis. Zhong Yao Cai. 2003;26:611–2.PubMed

46.

Gao BT. The effects of ligustrazine, aspirin and beta-histine on platelet aggregation in patients with acute ischemic stroke. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1989;22:148–51. 191.PubMed

47.

Wang XF, Zhao MQ. Ligustrazine and Salvia miltiorrhiza injection solution in complementary therapy of pregnancy-induced hypertension: clinical analysis of 60 cases. Di Yi Jun Yi Da Xue Xue Bao. 2003;23:969–71.PubMed

48.

Peng W, Duan SF. Effects of ligustrazine controlled release capsule in chronic pulmonary heart disease. J Tongji Med Univ. 1991;11:101–5.PubMedCrossRef

49.

Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006;47:3164–77.PubMedCrossRef

50.

Lee HJ, Noh YH, Lee DY, Kim YS, Kim KY, Chung YH, et al. Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Eur J Cell Biol. 2005;84:897–905.PubMedCrossRef

51.

Yang L, Sun HL, Wu LM, Guo XJ, Dou H, Tso MO, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:2319–27.PubMedCrossRef

52.

Wang SY, Wang HH, Chi CW, Chen CF, Liao JF. Effects of baicalein on beta-amyloid peptide-(25–35)-induced amnesia in mice. Eur J Pharmacol. 2004;506:55–61.PubMedCrossRef

53.

Sexton A, McDonald M, Cayla C, Thiemermann C, Ahluwalia A. 12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1. FASEB J. 2007;21:2695–703.PubMedCrossRef

54.

Wu PH, Shen YC, Wang YH, Chi CW, Yen JC. Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum. Toxicology. 2006;226:238–45.PubMedCrossRef

55.

Silva BA, Dias AC, Ferreres F, Malva JO, Oliveira CR. Neuroprotective effect of H. perforatum extracts on beta-amyloid-induced neurotoxicity. Neurotox Res. 2004;6:119–30.PubMedCrossRef

56.

Nakajima Y, Shimazawa M, Mishima S, Hara H. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci. 2007;80:370–7.PubMedCrossRef

57.

Bouayed J, Rammal H, Dicko A, Younos C, Soulimani R. Chlorogenic acid, a polyphenol from Prunus domestica (Mirabelle), with coupled anxiolytic and antioxidant effects. J Neurol Sci. 2007;262:77–84.PubMedCrossRef

58.

Ohnishi R, Ito H, Iguchi A, Shinomiya K, Kamei C, Hatano T, et al. Effects of chlorogenic acid and its metabolites on spontaneous locomotor activity in mice. Biosci Biotechnol Biochem. 2006;70:2560–3.PubMedCrossRef

59.

Mandal MN, Patlolla JM, Zheng L, Agbaga MP, Tran JT, Wicker L, et al. Curcumin protects retinal cells from light- and oxidant stress-induced cell death. Free Radic Biol Med. 2009;46:672–9.PubMedCrossRef

60.

Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med. 2008;44:907–17.PubMedCrossRef

61.

Matteucci A, Frank C, Domenici MR, Balduzzi M, Paradisi S, Carnovale-Scalzo G, et al. Curcumin treatment protects rat retinal neurons against excitotoxicity: effect on N-methyl-d-aspartate-induced intracellular Ca(2+) increase. Exp Brain Res. 2005;167:641–8.PubMedCrossRef

62.

Shukla PK, Khanna VK, Ali MM, Khan MY, Srimal RC. Anti-ischemic effect of curcumin in rat brain. Neurochem Res. 2008;33:1036–43.PubMedCrossRef

63.

Rathore P, Dohare P, Varma S, Ray A, Sharma U, Jaganathanan NR, et al. Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res. 2008;33:1672–82.PubMedCrossRef

64.

Lin HJ, Lai CC, Lee Chao PD, Fan SS, Tsai Y, Huang SY, et al. Aloe-emodin metabolites protected N-methyl-d-aspartate-treated retinal ganglion cells by Cu–Zn superoxide dismutase. J Ocul Pharmacol Ther. 2007;23:152–71.PubMedCrossRef

65.

Wang C, Zhang D, Ma H, Liu J. Neuroprotective effects of emodin-8-O-beta-d-glucoside in vivo and in vitro. Eur J Pharmacol. 2007;577:58–63.PubMedCrossRef

66.

Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K, et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol. 2006;168:1722–36.PubMedCrossRef

67.

Gu JW, Hasuo H, Takeya M, Akasu T. Effects of emodin on synaptic transmission in rat hippocampal CA1 pyramidal neurons in vitro. Neuropharmacology. 2005;49:103–11.PubMedCrossRef

68.

Soliman KF, Mazzio EA. In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc Soc Exp Biol Med. 1998;218:390–7.PubMed

69.

Zheng LT, Ock J, Kwon BM, Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008;8:484–94.PubMedCrossRef

70.

Park YH, Xu XR, Chiou GC. Structural requirements of flavonoids for increment of ocular blood flow in the rabbit and retinal function recovery in rat eyes. J Ocul Pharmacol Ther. 2004;20:189–200.PubMedCrossRef

71.

Dajas F, Rivera F, Blasina F, Arredondo F, Echeverry C, Lafon L, et al. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox Res. 2003;5:425–32.PubMedCrossRef

72.

Wang CN, Chi CW, Lin YL, Chen CF, Shiao YJ. The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons. J Biol Chem. 2001;276:5287–95.PubMedCrossRef

73.

Samhan-Arias AK, Martin-Romero FJ, Gutierrez-Merino C. Kaempferol blocks oxidative stress in cerebellar granule cells and reveals a key role for reactive oxygen species production at the plasma membrane in the commitment to apoptosis. Free Radic Biol Med. 2004;37:48–61.PubMedCrossRef

74.

Laabich A, Manmoto CC, Kuksa V, Leung DW, Vissvesvaran GP, Karliga I, et al. Protective effects of myricetin and related flavonols against A2E and light mediated-cell death in bovine retinal primary cell culture. Exp Eye Res. 2007;85:154–65.PubMedCrossRef

75.

Lopez-Sanchez C, Martin-Romero FJ, Sun F, Luis L, Samhan-Arias AK, Garcia-Martinez V, et al. Blood micromolar concentrations of kaempferol afford protection against ischemia/reperfusion-induced damage in rat brain. Brain Res. 2007;1182:123–37.PubMedCrossRef

76.

Chao HM, Lin DE, Chang Y, Hsu WM, Lee SM, Lee FL, et al. Ferulic acid, but not tetramethylpyrazine, significantly attenuates retinal ischemia/reperfusion-induced alterations by acting as a hydroxyl radical scavenger. J Ocul Pharmacol Ther. 2008;24:461–72.PubMedCrossRef

77.

Chen KJ, Chen K. Ischemic stroke treated with Ligusticum chuanxiong. Chin Med J (Engl). 1992;105:870–3.

78.

Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem. 2003;87:172–81.PubMedCrossRef

79.

Amaratunga A, Fine RE. Generation of amyloidogenic C-terminal fragments during rapid axonal transport in vivo of beta-amyloid precursor protein in the optic nerve. J Biol Chem. 1995;270:17268–72.PubMedCrossRef

80.

Gottlieb M, Leal-Campanario R, Campos-Esparza MR, Sanchez-Gomez MV, Alberdi E, Arranz A, et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol Dis. 2006;23:374–86.PubMedCrossRef

81.

Ibarretxe G, Sanchez-Gomez MV, Campos-Esparza MR, Alberdi E, Matute C. Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and protection by natural polyphenols. Glia. 2006;53:201–11.PubMedCrossRef

82.

Oyama Y, Fuchs PA, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 1994;635:125–9.PubMedCrossRef

83.

Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res. 2005;39:1119–25.PubMedCrossRef

84.

Chiou GC, Xu XR. Effects of some natural flavonoids on retinal function recovery after ischemic insult in the rat. J Ocul Pharmacol Ther. 2004;20:107–13.PubMedCrossRef

85.

Baluchnejadmojarad T, Roghani M. Effect of naringenin on intracerebroventricular streptozotocin-induced cognitive deficits in rat: a behavioral analysis. Pharmacology. 2006;78:193–7.PubMedCrossRef

86.

Tsai TY, Wu SN, Liu YC, Wu AZ, Tsai YC. Inhibitory action of L-type Ca2+ current by paeoniflorin, a major constituent of peony root, in NG108-15 neuronal cells. Eur J Pharmacol. 2005;523:16–24.PubMedCrossRef

87.

Li J, Xiong X, Liu Y. Protective effect of paeoniflorin against optic nerve crush. Journal of Huazhong University of Science and Technology. 2007;27:650–2.PubMedCrossRef

88.

Liu J, Jin DZ, Xiao L, Zhu XZ. Paeoniflorin attenuates chronic cerebral hypoperfusion-induced learning dysfunction and brain damage in rats. Brain Res. 2006;1089:162–70.PubMedCrossRef

89.

Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ. Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. Br J Pharmacol. 2006;148:314–25.PubMedCrossRef

90.

Tsuda T, Sugaya A, Ohguchi H, Kishida N, Sugaya E. Protective effects of peony root extract and its components on neuron damage in the hippocampus induced by the cobalt focus epilepsy model. Exp Neurol. 1997;146:518–25.PubMedCrossRef

91.

Dong LP, Wang TY. Effects of puerarin against glutamate excitotoxicity on cultured mouse cerebral cortical neurons. Zhongguo Yao Li Xue Bao. 1998;19:339–42.PubMed

92.

Lin F, Xin Y, Wang J, Ma L, Liu J, Liu C, et al. Puerarin facilitates Ca(2+)-induced Ca(2+) release triggered by KCl-depolarization in primary cultured rat hippocampal neurons. Eur J Pharmacol. 2007;570:43–9.PubMedCrossRef

93.

Teng Y, Cui H, Yang M, Song H, Zhang Q, Su Y, et al. Protective effect of puerarin on diabetic retinopathy in rats. Mol Biol Rep. 2008;36:1129–33.PubMedCrossRef

94.

Xuan B, Zhou YH, Yang RL, Li N, Min ZD, Chiou GC. Improvement of ocular blood flow and retinal functions with puerarin analogs. J Ocul Pharmacol Ther. 1999;15:207–16.PubMedCrossRef

95.

Xu XH, Zhao TQ. Effects of puerarin on d-galactose-induced memory deficits in mice. Acta Pharmacologica Sinica. 2002;23:587–90.PubMed

96.

Xu X, Zhang S, Zhang L, Yan W, Zheng X. The Neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. Planta Med. 2005;71:585–91.PubMedCrossRef

97.

Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res. 2000;32:115–24.PubMedCrossRef

98.

Schonlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol. 2001;24:161–71.PubMedCrossRef

99.

Spadea L, Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol. Phytother Res. 2001;15:219–23.PubMedCrossRef

100.

Veurink G, Liu D, Taddei K, Perry G, Smith MA, Robertson TA, et al. Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radic Biol Med. 2003;34:1070–7.PubMedCrossRef

101.

Kook D, Wolf AH, Yu AL, Neubauer AS, Priglinger SG, Kampik A, et al. The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest Ophthalmol Vis Sci. 2008;49:1712–20.PubMedCrossRef

102.

Areias FM, Rego AC, Oliveira CR, Seabra RM. Antioxidant effect of flavonoids after ascorbate/Fe(2+)-induced oxidative stress in cultured retinal cells. Biochem Pharmacol. 2001;62:111–8.PubMedCrossRef

103.

Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44:1982–92.PubMedCrossRef

104.

Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K, et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci. 2007;104:329–34.PubMedCrossRef

105.

Cho JY, Kim IS, Jang YH, Kim AR, Lee SR. Protective effect of quercetin, a natural flavonoid against neuronal damage after transient global cerebral ischemia. Neurosci Lett. 2006;404:330–5.PubMedCrossRef

106.

Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res. 2008;86:403–10.PubMedCrossRef

107.

Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005;37:349–50.PubMedCrossRef

108.

Mozaffarieh M, Grieshaber MC, Orgul S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol. 2008;53:479–505.PubMedCrossRef

109.

Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280:37377–82.PubMedCrossRef

110.

Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, et al. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci. 2007;14:256–60.PubMedCrossRef

111.

Almaas R, Saugstad OD, Pleasure D, Rootwelt T. Neuronal formation of free radicals plays a minor role in hypoxic cell death in human NT2-N neurons. Pediatr Res. 2002;51:136–43.PubMedCrossRef

112.

Nakamura N, Hayasaka S, Zhang XY, Nagaki Y, Matsumoto M, Hayasaka Y, et al. Effects of baicalin, baicalein, and wogonin on interleukin-6 and interleukin-8 expression, and nuclear factor-kappab binding activities induced by interleukin-1beta in human retinal pigment epithelial cell line. Exp Eye Res. 2003;77:195–202.PubMedCrossRef

113.

Cho J, Lee HK. Wogonin inhibits excitotoxic and oxidative neuronal damage in primary cultured rat cortical cells. Eur J Pharmacol. 2004;485:105–10.PubMedCrossRef

114.

Nagaki Y, Hayasaka S, Kadoi C, Nakamura N, Hayasaka Y. Effects of scutellariae radix extract and its components (baicalein, baicalin, and wogonin) on the experimental elevation of aqueous flare in pigmented rabbits. Jpn J Ophthalmol. 2001;45:216–20.PubMedCrossRef

115.

Shieh DE, Liu LT, Lin CC. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000;20:2861–5.PubMed

116.

Cho J, Lee HK. Wogonin inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Biol Pharm Bull. 2004;27:1561–4.PubMedCrossRef

Title: Neural protection by naturopathic compounds—an example of tetramethylpyrazine from retina to brain
Author: Zhiqun Tan
Publication date: 01-06-2009
Publisher: Humana Press Inc
Published in: Journal of Ocular Biology, Diseases, and Informatics / Issue 2/2009
Electronic ISSN: 1936-8445
DOI: https://doi.org/10.1007/s12177-009-9024-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neural protection by naturopathic compounds—an example of tetramethylpyrazine from retina to brain

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model

Immune maintenance in glaucoma: boosting the body’s own neuroprotective potential

Psychoneuroimmunology: application to ocular diseases

The two sides of cytokine signaling and glaucomatous optic neuropathy

Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease

An experiment of the combined treatment of traditional Lei-huo-jiu therapy with Chinese medicine for the lacrimal gland of Sjögren’s syndrome